ChemoMetec A/S (LON:0DZ0)

Market Cap	1.30B
Revenue (ttm)	56.95M
Net Income (ttm)	21.42M
Shares Out	n/a
EPS (ttm)	1.23
PE Ratio	60.56
Forward PE	49.40
Dividend	0.45 (0.07%)
Ex-Dividend Date	Oct 11, 2024

Volume	5,706
Average Volume	1,687
Open	611.00
Previous Close	582.25
Day's Range	609.00 - 640.25
52-Week Range	340.60 - 634.63
Beta	n/a
RSI	82.07
Earnings Date	Sep 11, 2025

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1997
• Employees: 174
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0DZ0

Financial Performance

In 2025, ChemoMetec's revenue was 495.57 million, an increase of 21.50% compared to the previous year's 407.87 million. Earnings were 186.41 million, an increase of 36.78%.

Financial numbers in DKK